If you’re looking to diversify outside of AI, especially as AI investors look to trim their winners to save up for that ...

Biotechnology stocks are among the most high-risk, high-reward stocks in the market. Many biotech companies are working to ...

Biotech stocks are attracting investors as M&A activity, valuations and upcoming catalysts help drive sector momentum.

Replimune has twice sought regulatory approval for its experimental melanoma drug, citing an unmet need for advanced ...

Both Agenus AGEN and Iovance Biotherapeutics IOVA are small-cap companies focused on next-generation cancer immunotherapies ...

Natera gets a buy rating reaffirmed, driven by robust expansion plans, recent FDA approval, and upgraded FY26 revenue ...

NTLA gains momentum after positive phase III data for its CRISPR therapy, while ADMA faces pricing and inventory pressure in IG markets.

Cory has been a professional trader for two decades. In addition to trading and investing he's widely published and coaches individual clients on the finer points of gaining an edge in the market.

Learning how to trade biotech stocks offers some of the most explosive profit opportunities in the entire market—but also some of its most punishing risks. Biotech stocks can double or triple ...

In 2025, biotechnology stocks had their best year since the COVID-19 pandemic, with the market sector’s two major indexes — the SDPR S&P Biotech ETX (NYSE: XBI) and iShares Biotech ETF (NYSE: IBB) — ...

As FDA activity accelerates and big pharma searches for its next generation of blockbuster drugs, select biotech companies are beginning to stand out from the crowd.

In 2025, biotechnology stocks had their best year since the COVID-19 pandemic, with the market sector's two major indexes - the SDPR S&P Biotech ETX (NYSE: XBI) and iShares Biotech ETF (NYSE: IBB) - ...